EGF +61 A>G polymorphism predicts complete pathologic response independent of KRAS status in locally advanced rectal cancer patients undergoing neoadjuvant cetuximab-based chemoradiation

Authors :: Vallböhmer, Daniel
Hu-Lieskovan, Siwen
Grimminger, Peter
Brabender, Jan
Hölscher, Arnulf H.
Semrau, Robert
Arnold, Dirk
Machiels, Jean-Pascal
Rödel, Claus
Velenik, Vaneja
Lenz, Heinz-Josef
Source :: 128. Kongress der Deutschen Gesellschaft für Chirurgie; 20110503-20110506; München; DOC11dgch346 /20110520/
Publication Year :: 2011
Publisher :: German Medical Science GMS Publishing House; Düsseldorf, 2011.
Abstract: Introduction: Cetuximab has demonstrated significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve local control or survival in locally advanced rectal cancer patients in recent phase I/II trials. In order to[for full text, please go to the a.m. URL]<br />128. Kongress der Deutschen Gesellschaft für Chirurgie

Subjects :: ddc: 610
610 Medical sciences
Medicine
neoplasms
digestive system diseases

Language :: English
Database :: OpenAIRE
Journal :: 128. Kongress der Deutschen Gesellschaft für Chirurgie; 20110503-20110506; München; DOC11dgch346 /20110520/
Accession number :: edsair.doi.dedup.....bb9fef72b3d4fa8cb481a956dfba0606
Full Text :: https://doi.org/10.3205/11dgch346

Full Text Access

Tools